Genocea Biosciences (GNCA) Trading Down 0%

Genocea Biosciences (NASDAQ:GNCA)’s share price traded down 0% during trading on Monday . The company traded as low as $0.81 and last traded at $0.81. 932,717 shares were traded during trading, a decline of 17% from the average session volume of 1,125,093 shares. The stock had previously closed at $0.81.

A number of equities analysts have recently commented on the stock. Zacks Investment Research raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, April 18th. Cantor Fitzgerald set a $5.00 target price on shares of Genocea Biosciences and gave the stock a “buy” rating in a research report on Sunday, March 11th. HC Wainwright started coverage on shares of Genocea Biosciences in a research report on Thursday, March 8th. They set a “buy” rating and a $5.00 target price on the stock. Robert W. Baird started coverage on shares of Genocea Biosciences in a research note on Monday, February 12th. They set an “outperform” rating and a $3.00 price objective on the stock. Finally, Needham & Company LLC upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research note on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $4.41.

How to Become a New Pot Stock Millionaire

The company has a debt-to-equity ratio of -1.26, a quick ratio of 0.83 and a current ratio of 0.83. The company has a market cap of $66.80, a PE ratio of -0.44 and a beta of 1.21.

Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings data on Friday, February 16th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.03. equities analysts expect that Genocea Biosciences will post -0.55 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System bought a new position in shares of Genocea Biosciences during the second quarter valued at approximately $265,000. Millennium Management LLC acquired a new stake in Genocea Biosciences in the fourth quarter valued at approximately $145,000. Finally, State Street Corp boosted its stake in Genocea Biosciences by 1,595.2% in the second quarter. State Street Corp now owns 366,172 shares of the biotechnology company’s stock valued at $1,912,000 after acquiring an additional 344,572 shares in the last quarter. Hedge funds and other institutional investors own 9.33% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at

About Genocea Biosciences

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform AnTigen Lead Acquisition System to design immunotherapies and vaccines that act through T cell immune responses. Its lead product candidate is GEN-003, an investigational immunotherapy that is in Phase III trial for the treatment of genital herpes infections.

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply